- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04015050
Randomised, Controlled Study to Assess Safety and Tolerance of Infant Formula With Prebiotics and Postbiotics in Healthy Infants. (WAVE)
A Randomised, Controlled, Double-blind, Parallel Group, Multi-country Study to Investigate the Safety and Tolerance of Infant Formula With Prebiotics and Postbiotics in Healthy Term Infants.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bialystok, Poland, 15-435
- Poliklinika Ginekologiczno-Położnicza Sp. z o.o. Sp. k.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. Healthy, singleton, term infants (gestational age ≥37 weeks + 0 days and ≤41weeks + 6 days);
2. Infants with age at screening ≤14 days;
3. Birth weight within 10th to 90th percentile per gestational age and sex, according to Intergrowth Standards;
4. Head circumference at screening within ±2 SD per age and sex according to WHO Child Growth Standards;
5. a Randomised groups: Infants who are exclusively formula fed and/or whose mothers have autonomously decided to exclusively formula feed, i.e. not to breastfeed or have ended breastfeeding before screening, and who are intending to exclusively formula feed at least till their infant is 17 weeks of age; OR b Breastfed reference group: Infants who are exclusively breastfed and whose mothers are intending to exclusively breastfeed at least till their infant is 17 weeks of age;
6. Written informed consent from parent(s) and/or legal guardian(s) aged ≥18 years at screening.
Exclusion Criteria:
1. Randomised groups: Infants who require a special diet other than non-hydrolysed, cow's milk based infant formula (e.g. due to known or suspected to have cow's milk allergy, soy allergy and/or lactose intolerance);
2. Infants with current or previous illnesses/conditions and/or known or suspected congenital diseases or malformations which could interfere with the study or its outcome parameters, such as but not limited to: GI malformations, congenital metabolic disorders, severe congenital cardiac disorders, immunodeficiency or major surgery, as per the clinical judgement of the Investigator;
3. Infants with previous, current or intended participation in any other clinical study involving investigational or marketed products;
4. Incapability of infants' parents to comply with study protocol as per the judgement of the Investigator;
5. Infants born from mothers known to have (any) hepatitis or human immunodeficiency virus;
6. Infants born from mothers with significant medical conditions during pregnancy that might interfere with the study or its outcome parameters or known to affect intra-uterine growth (e.g. placenta previa, pre-eclampsia, eclampsia, Type 1, 2 diabetes) as per clinical judgement of the Investigator;
7. Infants born from mothers, who did participate in any clinical study involving investigational products during pregnancy, and for infants in Breastfed reference group: mothers who are currently participating or intend to participate in any clinical study involving investigational products during lactation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Test product
Cow's milk based infant formula containing prebiotics and postbiotics
|
Cows milk ased infant formula
|
Active Comparator: Control product
Cow's milk based infant formula without prebiotics and postbiotics
|
Cows milk ased infant formula
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight gain
Time Frame: 17 weeks
|
from baseline until the age of 17 weeks (test product versus control product).
Weight gain will be calculated as weight (in grams) at visit minus weight at baseline divided by the number of days.
|
17 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- EBB18FI23464
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Term Infants
-
Heinz Italia SpAUniversity of Cagliari; IRCCS Policlinico S. MatteoCompletedFormula Feeding of Healthy Full Term Infants | Breast Feeding of Healthy Full Term InfantsItaly
-
NestléCompleted
-
ByHeartPaidion Research, Inc.CompletedHealthy | Term InfantsUnited States
-
Abbott NutritionCompleted
-
Abbott NutritionTerminatedHealthy Term InfantsUnited States
-
Mead Johnson NutritionCompleted
-
Universidad Autónoma de QuerétaroNUCITEC S.A. de C.V.CompletedGrowth & Development | Formula Feeding of Healthy Full Term Infants | Breast Feeding of Healthy Full Term InfantsMexico
-
Perrigo NutritionalsCompletedGrowth | Healthy Term InfantsUnited States
-
NestléTerminatedHealthy Full Term InfantsSouth Africa
-
Mead Johnson NutritionCompletedHealthy Term Infants Solely Formula FedUnited States
Clinical Trials on milk based infant formula
-
Medical University of WarsawAusnutria Hyproca B.V.Not yet recruitingGastrointestinal Diseases | Infant Nutrition DisordersPoland
-
Ausnutria Hyproca B.V.Completed
-
Mead Johnson NutritionBeijing Kangchen TechnologiesTerminated
-
Abbott NutritionInstitute of Child HealthCompleted
-
Abbott NutritionTerminatedHealthy Term InfantsUnited States
-
Mead Johnson NutritionWithdrawnGrowthUnited States
-
Mead Johnson NutritionUniversity of North Carolina, Chapel HillTerminatedDeclarative MemoryUnited States
-
Nutricia ResearchCompletedDiarrhea | Regurgitation, GastricItaly, Poland, Ukraine
-
Abbott NutritionCompleted